With LB Pharmaceuticals, Turner “liked the fact that it’s a very focused neuropsych company; this is where we’re going. And I also liked the fact that there was a near-term catalyst with our Phase 2 clinical program.” In other words, the company had a clear strategy in place; all it needed was a leader who could execute effectively.

Last year, Tessera Therapeutics’ CEO, Dr. Michael Severino, was my guest on Cell & Gene: The Podcast to discuss Gene Writing, the biotech’s genome

A private startup looking to bring an old schizophrenia drug class to the US has released new Phase 2 data and aims to start a …

LB Pharmaceuticals has shared top-line data from a phase 2 schizophrenia trial, touting results that offer early support for its vision and putting it on track to start a pivotal study around the end of the year.

MindMed announced the first patient had been dosed in the first-ever phase 3 trial of lysergic acid-diethylamide (LSD) for generalized anxiety disorder (GAD). MindMed is currently the furthest along in clinical trials exploring LSD as a treatment in multiple psychiatric indications, including major depressive disorder.

COUR Pharmaceuticals has been, as its newly-appointed President & CEO Dannielle Appelhans puts it, flying under the radar for a long time. COUR made a splash back in 2015, when it formed up around a biodegradable nanoparticle encapsulating gliadin proteins that proved to reverse the effects of gluten in animal models.

V.P. of R&D Tim Culp describes the rationale for in vivo CAR programs, what the company will be watching for from a safety standpoint, the development path ahead, and competition.